Ozempic and Vegovi may reduce the risk of strokes and heart attacks

New research shows that Ozempic and Wegovy may reduce the risk of strokes and heart attacks.Reuters

semaglutidea weight-loss drug commonly sold under the brand names Ozempic and Wegovy may help. reduce strokes and heart attacksas published in a new study published last Monday.

In particular, this two new analyzes which are part of a larger essay presented on May 13 at the European Congress on Obesity in Venice. Judging by the text, drug injections They reduced the risk of cardiovascular events such as strokes and heart attacks in adults with pre-existing conditions, regardless of weight loss, and helped people lose weight for at least four years.

Semaglutide is the main active ingredient of the drugs Ozempic and Vegovi., we remember. It mimics the hormone GLP-1, which can indicate that the body is full. The above two analyzes were conducted as part of the SELECT study, which enrolled more than 17,600 adults from 41 countries with pre-existing cardiovascular disease and overweight or obesity between October 2018 and March 2021. The entire process was funded by Novo Nordisk, the Danish pharmaceutical company that created the drug.

Two analyzes confirming the benefits of semaglutide

Patients from a “geographically and racially diverse population” took semaglutide and placebo once a week for an average of 3.3 years during the study. In progress 20% reduction in “major adverse cardiovascular events”, such as strokes, heart attacks and death from cardiovascular disease. A finding was published in the New England Journal of Medicine in 2023. These cardiovascular benefits were also independent of weight loss, according to the new study analysis, suggesting “alternative mechanisms for improved cardiovascular outcomes,” according to the new study analysis.

He another new essay analysisThe study, published this week in the journal Nature Medicine and presented at the conference, found that patients taking semaglutide “lost significantly more weight than those who received placebo.” The drug caused “clinically significant weight loss” and reduced waist size for at least four years in adults who were overweight or obese but did not have diabetes.

Donna RyanThe lead author of the analysis, from the Pennington Biomedical Research Center in the US, said at a press conference that the study showed that ” patients taking semaglutide have much more likely to not be obese after treatment with this drug.” Two years later, nearly 68% of patients taking the drug had lost 5% or more weight, and 44% had lost 10% or more.

This compared with 21% of those taking placebo lost five percent or more weight, and nearly 7% lost 10% or more weight. Ryan added that patients taking semaglutide had “fewer serious adverse events than placebo, primarily due to a reduction in cardiovascular events and infections.” He trial version, yes it had some limitations. People with excess body fat were not included, but people with a normal body mass index were included. The study puts concentrate also when using the drug in First aid.

Subscribe to the Informativos Telecinco newsletter and we will send you news to your email.

Follow us on our WhatsApp channel and stay updated with all the news at the moment.